{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/greater-trochanteric-pain-syndrome-trochanteric-bursitis/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"71e3ba74-5e5b-53af-90a2-64747eb09aea","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 00a98eb5-3618-4dd0-b21c-166266c5d322 --><h2>Changes</h2><!-- end field 00a98eb5-3618-4dd0-b21c-166266c5d322 -->","summary":null,"htmlStringContent":"<!-- begin item 17a14935-5253-4e19-8933-0988dad1af18 --><!-- begin field 32c5079d-91b7-492b-8c8e-3a857a6f12a6 --><p><strong>July to August 2016</strong> — reviewed. A literature search was conducted in July 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. Minor changes to the recommendations on management of greater trochanteric pain syndrome have been made.</p><!-- end field 32c5079d-91b7-492b-8c8e-3a857a6f12a6 --><!-- end item 17a14935-5253-4e19-8933-0988dad1af18 -->","topic":{"id":"f5b64608-cf1c-5e43-8737-57e5c43550a6","topicId":"312878ed-d57e-45ae-9e8d-d81933eef21e","topicName":"Greater trochanteric pain syndrome (trochanteric bursitis)","slug":"greater-trochanteric-pain-syndrome-trochanteric-bursitis","lastRevised":"Last revised in August 2016","chapters":[{"id":"93366306-a91c-5e3b-b2c9-c2ba25bd6c6a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"0793a5da-3642-58ce-b602-5e6bcd3d1fc0","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"db6919a8-9f39-59b7-90bb-8005f7a8f6a9","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"71e3ba74-5e5b-53af-90a2-64747eb09aea","slug":"changes","fullItemName":"Changes"},{"id":"3d3b603c-0380-5f28-9b95-f13574e76f3a","slug":"update","fullItemName":"Update"}]},{"id":"54aea975-a119-5ee3-8b76-439e722659bf","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"33b0bc5a-2a02-5111-8bac-32cb98e0edd9","slug":"goals","fullItemName":"Goals"},{"id":"e8e59fdd-81cd-58e5-ab1b-d12935423e34","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"151aa29e-1733-53b2-b17c-9218455ce895","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ed20ef05-d37e-502a-8689-79993edfc5ed","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d058cfb7-eb0b-5f86-9651-7d1b619f95bc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5d1fb9c1-8d6b-53fa-acc8-217e078359d5","slug":"nice-quality-standards","fullItemName":"NICE Quality Standards"}]},{"id":"2ee41038-4731-5ebb-a207-ae122da3c607","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"4291641d-ace5-5da8-80b1-e7fe14ce0986","slug":"definition","fullItemName":"Definition"},{"id":"488caa86-0f5d-5f04-b74d-c7cad8737ff0","slug":"causes","fullItemName":"Causes"},{"id":"bec80eec-9d11-581d-891f-cdc61d00fb8d","slug":"associated-conditions","fullItemName":"Associated conditions"},{"id":"380159dc-b5be-5c9f-bde7-8f30e44c4b7a","slug":"incidence-prevalence","fullItemName":"Incidence and prevalence"},{"id":"3413f952-6ab3-5674-8c56-90970afff5fc","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ef1e13b6-e28a-57a6-a8c1-d541a9e19bed","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ac73348d-f809-5f32-93ae-b2e83e8e3227","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"6d0d8f17-9ae7-5e34-a757-adf160bdae32","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3e1b1d0c-6cf5-5409-857b-0fee878194ae","fullItemName":"Management","slug":"management","subChapters":[{"id":"78a5772c-d4a0-54ad-8196-480e313e048b","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c7b85e3c-6820-5f01-a7c6-5414b0f1fa6e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"36478d75-f4ee-534d-ac6f-840edc462d38","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0d26623f-bf65-5e3b-a14d-7ff84a3d519e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"bef561b0-fdbb-5484-aaa5-79494ba00a8b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3c17a9f4-ea55-5f3a-b485-51b0c6224eb9","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2d7f998d-de79-5c94-9767-c1b1e084b390","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6315d5e8-01bb-5a01-88df-3d121d066f41","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"937a0c97-1412-5dee-bf5d-83a1498684c9","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"db6919a8-9f39-59b7-90bb-8005f7a8f6a9","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"891bb84d-8b97-58e8-95d0-3ba94653a42d","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field e091090f-23cd-4a4d-b169-7bd428d5258b --><h3>Previous changes</h3><!-- end field e091090f-23cd-4a4d-b169-7bd428d5258b -->","summary":null,"htmlStringContent":"<!-- begin item dfd0d5c8-d928-4f12-bebc-aa09230ef8a1 --><!-- begin field 6b2c7e7b-6b80-4720-ae39-0024dd8aed35 --><p><strong>July 2013 </strong>— minor update. Update to the text to reflect new recommendations by the MHRA regarding diclofenac <em>Diclofenac: new contraindications and warnings after a Europe-wide review of cardiovascular safety, 2013, Medicines and Healthcare products Regulatory Agency</em>.</p><p><strong>February 2013 </strong>— minor update. The 2013 QIPP options for local implementation have been added to this topic <em>Key therapeutic topics - medicines management for local implementation, 2013, National Institute for Health and Care Excellence</em>.</p><p><strong>October 2012</strong> — minor update. The 2012 QIPP options for local implementation have been added to this topic <em>Key therapeutic topics - medicines management options for local implementation, 2012, National Prescribing Centre</em>.</p><p><strong>May 2011</strong> — minor update. The 2010/2011 QIPP options for local implementation have been added to this topic <em>Key therapeutic topics 2010/2011 - Medicines management options for local implementation, 2011, National Prescribing Centre</em>.</p><p><strong>June to October 2010</strong> — this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 6b2c7e7b-6b80-4720-ae39-0024dd8aed35 --><!-- end item dfd0d5c8-d928-4f12-bebc-aa09230ef8a1 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}